Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $37.43

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned an average rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $37.43.

A number of analysts have commented on the company. Chardan Capital raised their price objective on Dyne Therapeutics from $20.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, March 8th. Raymond James raised their price target on Dyne Therapeutics from $27.00 to $56.00 and gave the company a “strong-buy” rating in a report on Thursday, January 4th. Oppenheimer reissued an “outperform” rating and issued a $47.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, March 26th. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, March 6th. Finally, Piper Sandler raised their price target on Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th.

Insider Activity

In other news, Director Jason P. Rhodes sold 177,906 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $23.89, for a total value of $4,250,174.34. Following the sale, the director now directly owns 7,148,211 shares in the company, valued at $170,770,760.79. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Susanna Gatti High sold 2,292 shares of Dyne Therapeutics stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $25.70, for a total value of $58,904.40. Following the sale, the chief operating officer now owns 156,800 shares of the company’s stock, valued at $4,029,760. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jason P. Rhodes sold 177,906 shares of Dyne Therapeutics stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $23.89, for a total value of $4,250,174.34. Following the completion of the sale, the director now directly owns 7,148,211 shares in the company, valued at approximately $170,770,760.79. The disclosure for this sale can be found here. Insiders have sold a total of 1,875,432 shares of company stock worth $44,368,530 over the last three months. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the business. Wetzel Investment Advisors Inc. acquired a new position in shares of Dyne Therapeutics in the first quarter valued at approximately $28,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Dyne Therapeutics by 5.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,921 shares of the company’s stock valued at $305,000 after purchasing an additional 1,199 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Dyne Therapeutics by 10.7% in the third quarter. Principal Financial Group Inc. now owns 15,229 shares of the company’s stock valued at $136,000 after purchasing an additional 1,476 shares during the last quarter. Profund Advisors LLC grew its position in shares of Dyne Therapeutics by 9.8% in the third quarter. Profund Advisors LLC now owns 23,793 shares of the company’s stock valued at $213,000 after purchasing an additional 2,131 shares during the last quarter. Finally, New York State Common Retirement Fund grew its position in shares of Dyne Therapeutics by 13.7% in the fourth quarter. New York State Common Retirement Fund now owns 18,592 shares of the company’s stock valued at $247,000 after purchasing an additional 2,244 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $24.73 on Wednesday. The firm has a market cap of $2.13 billion, a P/E ratio of -6.28 and a beta of 0.95. The stock’s 50-day moving average is $26.07 and its two-hundred day moving average is $17.70. Dyne Therapeutics has a fifty-two week low of $6.40 and a fifty-two week high of $30.27.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.17). As a group, research analysts expect that Dyne Therapeutics will post -3.25 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.